A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.
Cyclin-dependent kinase 12 (CDK12)/cyclin K and CDK13/cyclin K inhibitors have been described in a Nanjing Sanhome Pharmaceutical Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.
In what represents the first patenting to emerge from Braincapture ApS, its chief executive officer, Tue Lehn-Schiøler, describes the development of a low-cost, portable electroencephalogram device designed to enhance neurological diagnostics in underserved communities around the world.
Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.
Hainan Simcere Pharmaceutical Co. Ltd. has prepared bicyclic compounds acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease.
Oncozen Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising a heat shock protein 90 (HSP90) binding moiety covalently bound to hepatocyte growth factor receptor (HGFR; MET) targeting moiety through a linker.
In just the second PCT filing published in the name of Newmanbrain SL, co-founders Carlos Belmonte and Joaquin Ibañez seek specific protection for the use of Newmanbrain’s functional near infrared spectroscopy system, Theia, in the diagnosis of attention deficit/hyperactivity disorder.
RSS
